BridgeBio Pharma, Inc. (BBIO) stock
BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$78.17−1.37 (-1.72%)
Close on Nov 12, 2026Market cap $15.23BP/E –Yield –
BridgeBio Pharma ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
BridgeBio Pharma's ebitda for the twelve months ending Sep 30, 2026 was -$359.49M. For fiscal 2025 it was -$517.98M. The highest annual figure on record is -$265.38M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$517.98M | – |
| FY2024 | Dec 31, 2024 | -$586.90M | – |
| FY2023 | Dec 31, 2023 | -$600.88M | – |
| FY2022 | Dec 31, 2022 | -$505.43M | – |
| FY2021 | Dec 31, 2021 | -$570.79M | – |
| FY2020 | Dec 31, 2020 | -$473.03M | – |
| FY2019 | Dec 31, 2019 | -$265.38M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$10.57M | – |
| Q2 FY2026 | Jun 30, 2026 | -$106.03M | – |
| Q1 FY2026 | Mar 31, 2026 | -$104.77M | – |
| Q4 FY2025 | Dec 31, 2025 | -$138.13M | – |
| Q3 FY2025 | Sep 30, 2025 | -$143.80M | – |
| Q2 FY2025 | Jun 30, 2025 | -$132.96M | – |
| Q1 FY2025 | Mar 31, 2025 | -$103.09M | -5416.6% |
| Q4 FY2024 | Dec 31, 2024 | -$224.66M | – |
| Q3 FY2024 | Sep 30, 2024 | -$190.21M | – |
| Q2 FY2024 | Jun 30, 2024 | -$173.97M | – |
| Q1 FY2024 | Mar 31, 2024 | $1.94M | – |
| Q4 FY2023 | Dec 31, 2023 | -$175.83M | – |
| Q3 FY2023 | Sep 30, 2023 | -$156.05M | – |
| Q2 FY2023 | Jun 30, 2023 | -$144.46M | – |
| Q1 FY2023 | Mar 31, 2023 | -$124.53M | – |
| Q4 FY2022 | Dec 31, 2022 | -$127.57M | – |
| Q3 FY2022 | Sep 30, 2022 | -$127.47M | – |
| Q2 FY2022 | Jun 30, 2022 | -$78.59M | – |
| Q1 FY2022 | Mar 31, 2022 | -$171.79M | – |
| Q4 FY2021 | Dec 31, 2021 | -$164.09M | – |
| Q3 FY2021 | Sep 30, 2021 | -$149.23M | – |
| Q2 FY2021 | Jun 30, 2021 | -$90.53M | – |
| Q1 FY2021 | Mar 31, 2021 | -$166.94M | – |
| Q4 FY2020 | Dec 31, 2020 | -$127.05M | – |
| Q3 FY2020 | Sep 30, 2020 | -$120.95M | – |
| Q4 FY2019 | Dec 31, 2019 | -$78.40M | – |
See a number that looks wrong?